Pfizer (NYSE:PFE) Trading 1.1% Higher – Here’s What Happened

17 Jan 2026, 17:59 by Jessica Moore · The Cerbat Gem

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) traded up 1.1% during trading on Thursday . The company traded as high as $25.89 and last traded at $25.86. 54,988,627 shares changed hands during trading, an increase of 16% from the average session volume of 47,469,805 shares. The stock had previously closed at $25.58.

Analysts Set New Price Targets

A number of brokerages have commented on PFE. Scotiabank started coverage on Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $27.88.

Get Our Latest Stock Report on PFE

Pfizer Price Performance

The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company has a 50-day moving average of $25.35 and a 200-day moving average of $24.99. The stock has a market capitalization of $146.01 billion, a price-to-earnings ratio of 14.93 and a beta of 0.47.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Institutional Trading of Pfizer

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after buying an additional 10,198,330 shares in the last quarter. State Street Corp boosted its holdings in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Geode Capital Management LLC lifted its stake in Pfizer by 1.4% in the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after buying an additional 1,820,634 shares during the last quarter. Norges Bank acquired a new stake in shares of Pfizer in the 2nd quarter worth about $2,270,157,000. Finally, Northern Trust Corp grew its holdings in Pfizer by 1.4% in the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after buying an additional 869,175 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.